Tags

Type your tag names separated by a space and hit enter

[Recent advances in Parkinson disease].
Rev Neurol. 1999 Jul 16-31; 29(2):139-45.RN

Abstract

OBJECTIVE

To evaluate the latest advances in the diagnosis and symptomatic pharmacological treatment of patients with Parkinson's disease at different stages.

DEVELOPMENT

In this article we summarize the criteria for clinical diagnosis of Parkinson's disease based on recent clinico-pathological studies. We evaluate the different therapeutic options at early and late stages of the illness in view of the results of recent, controlled, double-blind studies in which the efficacy of new dopaminergic agonists (carbergolin, pramipexol and ropinirol) and catechol-O-methyl-transferase enzyme inhibitors (COMT; entacapone and tolcapone) are compared with placebo and with established treatments (e.g. levodopa and bromocryptin).

CONCLUSIONS

Levodopa is still the most important advance yet made in the treatment of Parkinson's disease, but new dopaminergic agonists and COMT inhibitors are useful additions to the possibilities available for the treatment of early and late stages of the illness and may be included in modern guidelines for treatment.

Authors+Show Affiliations

Unidad de Neurofarmacología, Henry M. Jackson Foundation, Bethesda, MD, USA. litvan1@helix.nih.gov

Pub Type(s)

Journal Article
Review

Language

spa

PubMed ID

10528328

Citation

Litvan, I. "[Recent Advances in Parkinson Disease]." Revista De Neurologia, vol. 29, no. 2, 1999, pp. 139-45.
Litvan I. [Recent advances in Parkinson disease]. Rev Neurol. 1999;29(2):139-45.
Litvan, I. (1999). [Recent advances in Parkinson disease]. Revista De Neurologia, 29(2), 139-45.
Litvan I. [Recent Advances in Parkinson Disease]. Rev Neurol. 1999 Jul 16-31;29(2):139-45. PubMed PMID: 10528328.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Recent advances in Parkinson disease]. A1 - Litvan,I, PY - 1999/10/21/pubmed PY - 1999/10/21/medline PY - 1999/10/21/entrez SP - 139 EP - 45 JF - Revista de neurologia JO - Rev Neurol VL - 29 IS - 2 N2 - OBJECTIVE: To evaluate the latest advances in the diagnosis and symptomatic pharmacological treatment of patients with Parkinson's disease at different stages. DEVELOPMENT: In this article we summarize the criteria for clinical diagnosis of Parkinson's disease based on recent clinico-pathological studies. We evaluate the different therapeutic options at early and late stages of the illness in view of the results of recent, controlled, double-blind studies in which the efficacy of new dopaminergic agonists (carbergolin, pramipexol and ropinirol) and catechol-O-methyl-transferase enzyme inhibitors (COMT; entacapone and tolcapone) are compared with placebo and with established treatments (e.g. levodopa and bromocryptin). CONCLUSIONS: Levodopa is still the most important advance yet made in the treatment of Parkinson's disease, but new dopaminergic agonists and COMT inhibitors are useful additions to the possibilities available for the treatment of early and late stages of the illness and may be included in modern guidelines for treatment. SN - 0210-0010 UR - https://www.unboundmedicine.com/medline/citation/10528328/[Recent_advances_in_Parkinson_disease]_ L2 - http://www.diseaseinfosearch.org/result/5603 DB - PRIME DP - Unbound Medicine ER -